🤩

Thank you American College of Cardiology Massachusetts ACC Colleen Harrington MD, FACC, FASE Omar K. Siddiqi, MD, FACC for a great conference The Liberty, A Luxury Collection Hotel to promote our professional development in cardiology: leveraging social media w Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦, navigating mentorship w Jennifer Ho and fostering innovation w Ami Bhatt, MD!

Super informative and motivating workshop Massachusetts ACC Big thank you to Omar K. Siddiqi, MD, FACC Colleen Harrington MD, FACC, FASE and amazing speakers Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 Reena Pande Ami Bhatt, MD Jennifer Ho

Lasix pump. What do heart failure folks think about this? Dmitry Abramov Diane Tran MD Anju Bhardwaj MD FACC Anu Lala-Trindade Robert Mentz, MD Nasrien E. Ibrahim, MD Harriette Van Spall, MD MPH Shelley Zieroth

FDA Approves Wearable Furosemide Delivery System Furoscix for Outpatient Use empr.com/home/news/fda-…

I don’t usually weigh in on non-neurology debates but thought I would fix a typo in this title

Live case at #TCT22 from #bicath Beth Israel Lahey Health with Robert W. Yeh MD and our fellow Serge Korjian M.D.

Congratulations to all #EAST trial investigators!

Attaining SR mediates improved outcome in #EAST
👉🏻 #EHJ bit.ly/3Az2Pzc

See here our #Editorial on this late breaking science manuscript
📖 bit.ly/3cvjXOA
William F McIntyre

European Society of Cardiology European Society of Cardiology Journals EHJ Editor-in-Chief

#ESCCongress

Wearable tech improved the detection of Afib in elderly patients: eBRAVE-AF trial shows.

Commentary and analysis by Enrico Ferro, MD

cardiologynownews.org/its-time-to-ra…

C. Michael Gibson MD

Oral FXIa Inhibitor Milvexian did not increase bleeding events when added to antiplatelet therapy after acute stroke, results from the phase 2 AXIOMATIC-SSP trial:

Summary and analysis by Enrico Ferro, MD

cardiologynownews.org/uncoupling-hem…

C. Michael Gibson MD

Take home messages on Factor xi inhibition trials:

1. These were modest sized phase 2 trials to look at PK / PD (drug levels & bio markers) and SAFETY of different doses.

2. These trials are not big enough to say if the drugs are or are not effective.

Asundexian, a Factor XIa inhibitor, did not reduce recurrent strokes, but showed a dose-dependent decrease in TIAs in the phase 2 PACIFIC-STROKE.

Commentary and analysis by Enrico Ferro, MD

cardiologynownews.org/uncoupling-hem…

C. Michael Gibson MD

Rivaroxaban confers a higher mortality risk in patients with rheumatic mitral stenosis when compared to warfarin: INVICTUS shows.

Analysis and commentary by Enrico Ferro, MD

cardiologynownews.org/an-answer-at-l…

C. Michael Gibson MD

PACIFIC-AMI: Asundexian found to successfully inhibit Factor XIa without increased bleeding events, when added to DAPT after MI:

Summary and analysis by Enrico Ferro, MD

cardiologynownews.org/uncoupling-hem…

C. Michael Gibson MD

#EPeeps LBCT at #ESC2022 in Barcelona. Peter Kistler presenting CAPLA. PVI vs PVI + PWI. No differences in primary outcome, persistent AF, or AF burden. Wow.